Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study
Research output: Contribution to journal › Article › peer-review
Standard
Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis : a pilot study. / Sandoo, Aamer; Veldhuijzen van Zanten, Jet J C S; Toms, Tracey E; Carroll, Douglas; Kitas, George D.
In: BMC Musculoskeletal Disorders, Vol. 13, 2012, p. 127.Research output: Contribution to journal › Article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis
T2 - a pilot study
AU - Sandoo, Aamer
AU - Veldhuijzen van Zanten, Jet J C S
AU - Toms, Tracey E
AU - Carroll, Douglas
AU - Kitas, George D
PY - 2012
Y1 - 2012
N2 - Rheumatoid arthritis (RA) is associated with increased morbidity and mortality from cardiovascular disease (CVD). This can be only partially attributed to traditional CVD risk factors such as dyslipidaemia and their downstream effects on endothelial function. The most common lipid abnormality in RA is reduced levels of high-density lipoprotein (HDL) cholesterol, probably due to active inflammation. In this longitudinal study we hypothesised that anti-tumor necrosis factor-α (anti-TNFα) therapy in patients with active RA improves HDL cholesterol, microvascular and macrovascular endothelial function.
AB - Rheumatoid arthritis (RA) is associated with increased morbidity and mortality from cardiovascular disease (CVD). This can be only partially attributed to traditional CVD risk factors such as dyslipidaemia and their downstream effects on endothelial function. The most common lipid abnormality in RA is reduced levels of high-density lipoprotein (HDL) cholesterol, probably due to active inflammation. In this longitudinal study we hypothesised that anti-tumor necrosis factor-α (anti-TNFα) therapy in patients with active RA improves HDL cholesterol, microvascular and macrovascular endothelial function.
U2 - 10.1186/1471-2474-13-127
DO - 10.1186/1471-2474-13-127
M3 - Article
C2 - 22824166
VL - 13
SP - 127
JO - BMC Musculoskeletal Disorders
JF - BMC Musculoskeletal Disorders
SN - 1471-2474
ER -